Cytokinetics宣布Myqorzo™(Aficamten)在美国上市,用于治疗成人症状性梗阻性肥厚型心肌病以改善功能能力和症状

美股速递
Jan 27

Cytokinetics公司宣布,其创新药物Myqorzo™(Aficamten)现已在美国市场正式推出。该药物专为成人症状性梗阻性肥厚型心肌病(HCM)患者设计,旨在显著提升患者的功能能力并有效缓解相关症状。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10